

Grant A McArthur

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1872815/grant-a-mcarthur-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

145
papers

36,378
citations

56
h-index

153
g-index

153
ext. papers

42,465
ext. citations

11.2
avg, IF

6.64
L-index

#	Paper	IF	Citations
145	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. <i>New England Journal of Medicine</i> , 2011 , 364, 2507-16	59.2	5851
144	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015 , 373, 23-34	59.2	5047
143	Inhibition of mutated, activated BRAF in metastatic melanoma. <i>New England Journal of Medicine</i> , 2010 , 363, 809-19	59.2	2871
142	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1345-1356	59.2	2030
141	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. <i>Lancet, The</i> , 2006 , 368, 1329-38	40	2004
140	Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. <i>New England Journal of Medicine</i> , 2012 , 366, 707-14	59.2	1697
139	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. <i>Nature</i> , 2010 , 468, 973-7	50.4	1678
138	Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. <i>New England Journal of Medicine</i> , 2014 , 371, 1867-76	59.2	1403
137	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. <i>Nature</i> , 2010 , 467, 596-9	50.4	1379
136	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 1535-1546	59.2	1260
135	Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. <i>Cancer Cell</i> , 2010 , 18, 683-95	24.3	1007
134	RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. <i>New England Journal of Medicine</i> , 2012 , 366, 207-15	59.2	838
133	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology, The</i> , 2014 , 15, 323-32	21.7	753
132	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. <i>Lancet Oncology, The</i> , 2018 , 19, 672-681	21.7	512
131	Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. <i>Journal of Clinical Oncology</i> , 2005 , 23, 866-73	2.2	374
130	Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 10697-702	11.5	373
129	Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. <i>Cancer Cell</i> , 2012 , 22, 51-65	24.3	368

128	mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. <i>Molecular and Cellular Biology</i> , 2003 , 23, 8862-77	4.8	349
127	RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. <i>Journal of Clinical Oncology</i> , 2012 , 30, 316-21	2.2	318
126	Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1767-74	2.2	295
125	Melanoma. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15003	51.1	283
124	Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. <i>Archives of Dermatology</i> , 2006 , 142, 1551-8		226
123	Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. <i>Journal of Clinical Investigation</i> , 2013 , 123, 1371-81	15.9	226
122	Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. <i>Lancet Oncology</i> , 2014 , 15, 954-65	21.7	197
121	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. <i>Cancer Research</i> , 2015 , 75, 5228-34	10.1	196
120	The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. <i>Clinical Cancer Research</i> , 2013 , 19, 5320-8	12.9	182
119	Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. <i>Cancer Discovery</i> , 2014 , 4, 423-33	24.4	180
118	Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2375-83	2.2	175
117	Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. <i>BMC Medical Genomics</i> , 2014 , 7, 23	3.7	170
116	Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2011 , 24, 666-72	4.5	168
115	MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. <i>EMBO Journal</i> , 2004 , 23, 3325-35	13	153
114	Dysregulation of the basal RNA polymerase transcription apparatus in cancer. <i>Nature Reviews Cancer</i> , 2013 , 13, 299-314	31.3	147
113	Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1628-34	2.2	141
112	Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. <i>Pigment Cell and Melanoma Research</i> , 2014 , 27, 590-600	4.5	133
111	Phenotype switching in melanoma: implications for progression and therapy. <i>Frontiers in Oncology</i> , 2015 , 5, 31	5.3	111

110	Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. <i>Clinical Cancer Research</i> , 2009 , 15, 2166-73	12.9	111
109	AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer. <i>Science Signaling</i> , 2011 , 4, ra56	8.8	104
108	Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. <i>Cancer Research</i> , 2006 , 66, 8219-26	10.1	104
107	Dermatofibrosarcoma protuberans: recent clinical progress. <i>Annals of Surgical Oncology</i> , 2007 , 14, 2876-86	3.6	103
106	BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. <i>Clinical Cancer Research</i> , 2013 , 19, 4589-98	12.9	102
105	Combined CDK4/6 and PI3K inhibition is synergistic and immunogenic in triple-negative breast cancer. <i>Cancer Research</i> , 2017 , 77, 6340-6352	10.1	99
104	Negative cell-cycle regulators cooperatively control self-renewal and differentiation of haematopoietic stem cells. <i>Nature Cell Biology</i> , 2005 , 7, 172-8	23.4	95
103	BRAF, a target in melanoma: implications for solid tumor drug development. <i>Cancer</i> , 2010 , 116, 4902-136.4	6.4	92
102	EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 55, 713-23	4	91
101	Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. <i>Pigment Cell and Melanoma Research</i> , 2010 , 23, 210-5	4.5	88
100	The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 67-77	8.8	84
99	The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. <i>Science Signaling</i> , 2015 , 8, ra82	8.8	82
98	Targeting oncogenic drivers and the immune system in melanoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 499-506	2.2	82
97	Novel combination therapies for BRAF-mutant melanoma. <i>Journal of Translational Medicine</i> , 2015 , 13, K6	8.5	78
96	c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation. <i>Nucleic Acids Research</i> , 2011 , 39, 3267-81	20.1	76
95	Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. <i>Cancer Discovery</i> , 2016 , 6, 59-70	24.4	73
94	Review: mucosal melanoma of the head and neck. <i>Melanoma Research</i> , 2011 , 21, 257-66	3.3	66
93	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8502-8502	2.2	65

92	The state of melanoma: challenges and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016 , 29, 404-16	4.5	63
91	Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. <i>Oncotarget</i> , 2016 , 7, 49800-49818	3.3	62
90	Molecularly targeted treatment for dermatofibrosarcoma protuberans. <i>Seminars in Oncology</i> , 2004 , 31, 30-6	5.5	57
89	MAD1 and p27(KIP1) cooperate to promote terminal differentiation of granulocytes and to inhibit Myc expression and cyclin E-CDK2 activity. <i>Molecular and Cellular Biology</i> , 2002 , 22, 3014-23	4.8	56
88	Cell cycle control as a promising target in melanoma. <i>Current Opinion in Oncology</i> , 2015 , 27, 141-50	4.2	52
87	Targeting NRAS in melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012 , 18, 132-6	2.2	51
86	Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, e104-6	2.2	46
85	A community-based model of rapid autopsy in end-stage cancer patients. <i>Nature Biotechnology</i> , 2016 , 34, 1010-1014	44.5	46
84	Radiotherapy complements immune checkpoint blockade. <i>Cancer Cell</i> , 2015 , 27, 437-8	24.3	45
83	Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. <i>Medical Journal of Australia</i> , 2014 , 201, 49-53	4	44
82	Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. <i>BMJ Case Reports</i> , 2016 , 2016,	0.9	42
81	Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance. <i>International Journal of Cancer</i> , 2018 , 142, 2139-2152	7.5	41
80	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102229	2.2	39
79	Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours. <i>Scientific Reports</i> , 2013 , 3, 3494	4.9	38
78	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. <i>European Journal of Cancer</i> , 2018 , 105, 88-102	7.5	37
77	Molecular Genomic Profiling of Melanocytic Nevi. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 1762-1768	17.68	36
76	Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006 , 33, 441-52	8.8	36
75	Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. <i>Current Opinion in Oncology</i> , 2006 , 18, 341-6	4.2	36

74	BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 249-54	7.3	35
73	Targeting the nucleolus for cancer-specific activation of p53. <i>Drug Discovery Today</i> , 2014 , 19, 259-65	8.8	34
72	Tumour mutation status and sites of metastasis in patients with cutaneous melanoma. <i>British Journal of Cancer</i> , 2017 , 117, 1026-1035	8.7	33
71	Cell Cycle Regulation and Melanoma. <i>Current Oncology Reports</i> , 2016 , 18, 34	6.3	32
70	Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. <i>Oncotarget</i> , 2016 , 7, 46492-46508	3.3	29
69	TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. <i>Oncotarget</i> , 2014 , 5, 10127-39	3.3	28
68	An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021 , 17, 359-367	1.9	27
67	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma.. <i>JCO Precision Oncology</i> , 2017 , 1, 1-14	3.6	25
66	Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX vaccine in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 507-18	7.4	24
65	The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound. <i>Cell Reports</i> , 2014 , 7, 1009-19	10.6	24
64	Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death-1 monoclonal antibodies for advanced melanoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017 , 13, 385-390	1.9	24
63	Targeting metabolic reprogramming as a potential therapeutic strategy in melanoma. <i>Pharmacological Research</i> , 2016 , 107, 42-47	10.2	24
62	The current state of targeted therapy in melanoma: this time it's personal. <i>Seminars in Oncology</i> , 2012 , 39, 204-14	5.5	22
61	Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet. <i>Frontiers in Oncology</i> , 2015 , 5, 161	5.3	22
60	Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma. <i>Oncotarget</i> , 2015 , 6, 1115-27	3.3	22
59	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. <i>European Journal of Cancer</i> , 2015 , 51, 852-60	7.5	21
58	Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation. <i>Communications Biology</i> , 2019 , 2, 39	6.7	18
57	Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. <i>Current Opinion in Immunology</i> , 2016 , 39, 30-8	7.8	18

56	Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly. <i>FASEB Journal</i> , 2015 , 29, 1426-34	0.9	17
55	Applications of positron emission tomography in the development of molecular targeted cancer therapeutics. <i>BioDrugs</i> , 2003 , 17, 339-54	7.9	16
54	Co-targeting deoxyribonucleic acid-dependent protein kinase and poly(adenosine diphosphate-ribose) polymerase-1 promotes accelerated senescence of irradiated cancer cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 385-94	4	15
53	Bioinformatics pipelines for targeted resequencing and whole-exome sequencing of human and mouse genomes: a virtual appliance approach for instant deployment. <i>PLoS ONE</i> , 2014 , 9, e95217	3.7	15
52	A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 493-503	3.5	14
51	Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8503-8503	2.2	14
50	Decline in cancer pathology notifications during the 2020 COVID-19-related restrictions in Victoria. <i>Medical Journal of Australia</i> , 2021 , 214, 281-283	4	14
49	Cell division and hematopoietic stem cells: not always exhausting. <i>Cell Cycle</i> , 2005 , 4, 893-6	4.7	13
48	Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series. <i>Health Science Reports</i> , 2019 , 2, e115	2.2	12
47	Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma. <i>Histopathology</i> , 2013 , 63, 351-61	7.3	12
46	CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory. <i>Cancer Discovery</i> , 2021 , 11, 2582-2601	24.4	12
45	BRAF-targeted therapy and immune responses to melanoma. <i>Oncotarget</i> , 2013 , 2, e24462	7.2	11
44	Correlation of subjective self-reported melanoma growth rate with objective tumor proliferation markers. <i>Archives of Dermatology</i> , 2008 , 144, 555-6		11
43	CDK4 inhibitors an emerging strategy for the treatment of melanoma. <i>Melanoma Management</i> , 2015 , 2, 255-266	2.1	10
42	Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma. <i>International Journal of Cancer</i> , 2020 , 147, 2176-2189	7.5	10
41	Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901. <i>Nuclear Medicine and Biology</i> , 2014 , 41, 148-54	2.1	10
40	Targeted therapies for cutaneous melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014 , 28, 491-505	3.1	10
39	Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer. <i>Future Oncology</i> , 2008 , 4, 211-7	3.6	10

38	Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management*. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2007 , 3, 167-176	1.9	10
37	5-Year Outcomes with Cobimetinib plus Vemurafenib in Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. <i>Clinical Cancer Research</i> , 2021 ,	12.9	10
36	Adjuvant immunotherapy for cancer: the next step. <i>Lancet Oncology, The</i> , 2015 , 16, 478-80	21.7	9
35	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma 2020 , 8,		9
34	Integration of Immuno-Oncology and Palliative Care. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1561-2	2.2	9
33	Clinical significance of genomic alterations of the CDK4-pathway and sensitivity to the CDK4 inhibitor PD 0332991 in melanoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8520-8520	2.2	9
32	A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy. <i>Scientific Reports</i> , 2019 , 9, 1225	4.9	8
31	Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma: A Retrospective Study of Primary Tumor Characteristics. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 90-94 ⁷		7
30	An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8517-8517	2.2	7
29	Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. <i>Frontiers in Immunology</i> , 2021 , 12, 661737	8.4	7
28	Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma. <i>Cancer Immunology Research</i> , 2021 , 9, 136-146	12.5	7
27	Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy. <i>British Journal of Cancer</i> , 2018 , 118, 1289-1295	8.7	7
26	The coming of age of MEK. <i>Lancet Oncology, The</i> , 2012 , 13, 744-5	21.7	6
25	Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. <i>Journal of Personalized Medicine</i> , 2012 , 2, 35-49	3.6	6
24	The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas. <i>Expert Review of Molecular Diagnostics</i> , 2008 , 8, 105-19	3.8	6
23	Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES) 2021 , 9,		5
22	Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma 2020 , 8,		5
21	A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 869-877.e16	4.3	5

20	Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation - AuthorsReply. <i>Lancet Oncology, The</i> , 2018 , 19, e367	21.7	4
19	Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9050-9050	2.2	4
18	An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic		4
17	High-resolution MRI demonstrates that more than 90% of small intracranial melanoma metastases develop in close relationship to the leptomeninges. <i>Neuro-Oncology</i> , 2020 , 22, 423-432	1	3
16	Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting. <i>Internal Medicine Journal</i> , 2018 , 48, 786-794	1.6	3
15	Consensus approaches to best practice management of gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008 , 4, 188-198	1.9	3
14	A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10061-10061	2.2	3
13	T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival. <i>Cancer Immunology Research</i> , 2021 , 9, 612-623	12.5	3
12	Inhibition of RNA Polymerase I Transcription by CX-5461 As a Therapeutic Strategy for the Cancer-Specific Activation of p53 in MLL-Rearranged Acute Myeloid Leukemias. <i>Blood</i> , 2011 , 118, 1548-1548	2.2	2
11	Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. <i>European Journal of Cancer</i> , 2021 , 156, 149-163	7.5	2
10	Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma.. <i>Cancers</i> , 2021 , 13,	6.6	2
9	Concordance of somatic mutational profile in multiple primary melanomas. <i>Pigment Cell and Melanoma Research</i> , 2018 , 31, 592-603	4.5	1
8	Splicing the way to leukemia with KIT. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1431-2	1.9	1
7	Is resistance to targeted therapy in cancer inevitable?. <i>Cancer Cell</i> , 2021 , 39, 1047-1049	24.3	1
6	Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?. <i>Npj Precision Oncology</i> , 2022 , 6, 26	9.8	0
5	Lymphatic and Hematogenous Dissemination in Patients With Primary Cutaneous Melanoma. <i>JAMA Dermatology</i> , 2019 , 155, 1322	5.1	
4	In response to Drs. Krause, Baumann, and Thames. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 57, 301	4	
3	Management of Melanoma 2017 , 15-23		

2 Pathology of Melanoma **2017**, 9-13

- 1 Evaluation of cyclophosphamide as an immune enhancer for the NY-ESO-1/ISCOMATRIX vaccine in patients with metastatic melanoma.. *Journal of Clinical Oncology*, **2013**, 31, 3093-3093

2.2